2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

In vivo and In vitro study of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats : A therapeutic potential drug for Alzheimer’s disease

P. Kumar, N. Baquer (New Delhi, India)

Neuropharmacology  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.

F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data

R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data

F. Ikedo, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data

R. Costa, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to gender: post-hoc analysis from double-blind combined BIPARK-I and II data

F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.

R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

IncobotulinumtoxinA is effective, long lasting and well tolerated treatment of hemifacial spasm

S. Ochudlo, A. Krzak-Kubica, J. Gawryluk (Katowice, Poland)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Incongruity of Functional Tremor Predicts Better Response to Transcranial Magnetic Stimulation Treatment

N. Prezelj, K. Vogelnik, Z. Pirtošek, M. Kojović (Ljubljana, Slovenia)

Functional (Psychogenic) Movement Disorders  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Increased level of a lysosomal phospholipid, BMP, in urine of LRRK2 G2019S mutation carriers with or without Parkinson’s disease: implications for therapeutic development

R. Alcalay, F. Hsieh, S. Padmanabhan, M. Baptista, C. Kehow, S. Narayan, A. Boehme, K. Merchant (Cambridge, MA, USA)

Gene and Cell-Based Therapies  ·  Les Muses Terrace, Level 3